Equillium Results Presentation Deck

Itolizumab added to SoC Shows Clinically Meaningful Benefit EULAR/ERA-EDTA treatment goals for patients with lupus nephritis AMP SOC data2,3 (Mean baseline UPCR -3.4) EULAR/ERA-EDTA Treatment Duration equillium 3 months 6 months 12 months Treatment Goal¹ Reduction in proteinuria at least 25% Partial clinical response 50% reduction in proteinuria Complete clinical response Proteinuria < 0.5 g/g Proteinuria < 0.7 g/g Complete clinical response Proteinuria < 0.5 g/g Proteinuria < 0.7 g/g Not reported 52 of 121 (43%) 28 of 121 (23%) Not reported 34 of 121 (28%) Not reported Abbreviations: EOS, end of study: SoC, Standard of Care Itolizumab based on interim data from 2 Sep 2022-subject to change 1. Fanouriakis A, et al. Ann Rheum Dis. 2020; 2. Izmirly et al., Arthritis Rheumatol. 2021; 3. Carlucci et al., Arthritis Rheumatol. 2020 Itolizumab Interim Analysis (Mean baseline UPCR -5.8) 7 of 11 (64%) by Week 12 5 of 6 (83%) by Week 28/ EOS 2 of 12 (17%) 4 of 12 (33%) Dosing completed at 6 mo 30

View entire presentation